Evidence map›Paper›PMID 28894136›Full record

ArticleScientific reports2017

Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers.

Vincent L Chen, An K Le, Ondrej Podlaha, Jacqueline Estevez, Biao Li, Philip Vutien, Ellen T Chang, Yael Rosenberg-Hasson, Stefan Pflanz, Zhaoshi Jiang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. The Biomarkers for Predicting Viral HepatitisAssociated Hepatocellular Carcinoma.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. BiomarkersWorld journal of clinical cases · 2019
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Vincent L ChenDepartment of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
An K LeDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Ondrej PodlahaGilead Sciences, Foster City, CA, USA.
Jacqueline EstevezDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
Biao LiGilead Sciences, Foster City, CA, USA.
Philip VutienDepartment of Medicine, Rush University Medical Center, Chicago, IL, USA.
Ellen T ChangDepartment of Health Research and Policy (Epidemiology), Stanford University School of Medicine, Stanford, CA, USA.
Yael Rosenberg-HassonInstitute for Immunity, Transplantation, and Infection Operations, Stanford University School of Medicine, Stanford, CA, USA.
Stefan PflanzGilead Sciences, Foster City, CA, USA.
Zhaoshi JiangGilead Sciences, Foster City, CA, USA.
Dongliang GeGilead Sciences, Foster City, CA, USA.
Anuj GaggarGilead Sciences, Foster City, CA, USA.
Mindie H NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. mindiehn@stanford.edu.
Gilead Sciences (United States) · USStanford University · USStanford Medicine · USRush University Medical Center · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

Individualized assessment of hepatocellular carcinoma (HCC) risk in chronic liver disease remains challenging. Serum biomarkers including cytokines may offer helpful adjuncts to standard parameters for risk prediction. Our aim was to identify markers associated with increased HCC incidence. This was a prospective cohort study of 282 patients with both viral or non-viral chronic liver disease. Baseline serum cytokines and other markers were measured in multiplex with a commercially-available Luminex-based system. Patients were followed until death or HCC diagnosis. We performed Lasso-based survival analysis to determine parameters associated with HCC development. Cytokine mean florescence intensity (MFI) was the primary predictor and HCC development the primary outcome. 25 patients developed HCC with total follow-up of 1,363 person-years. Parameters associated with increased HCC incidence were cirrhosis, hepatic decompensation, and soluble serum intercellular adhesion molecule 1 (sICAM-1) MFI. No other molecules increased predictive power for HCC incidence. On univariate analysis, the parameters associated with HCC incidence in patients with cirrhosis were age, antiviral treatment, and high sICAM-1 MFI; on multivariate analysis, sICAM-1 remained associated with HCC development (adjusted HR = 2.75). On unbiased screening of serum cytokines and other markers in a diverse cohort, baseline sICAM-1 MFI is associated with HCC incidence.

Indexed as

AdultAgedBiomarkersCarcinoma, HepatocellularFemaleHumansIncidenceIntercellular Adhesion Molecule-1Liver NeoplasmsMaleMiddle AgedProspective StudiesRisk AssessmentBiomarkersIntercellular Adhesion Molecule-1

Identifiers

PMID28894136
PMCPMC5593940
OpenAlexW2752556614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.